论文部分内容阅读
目的观察吉西他滨联合顺铂方案治疗对蒽环类及紫杉醇类均耐药的转移性乳腺癌的疗效及不良反应。方法 36例晚期乳腺癌患者均应用过紫杉醇类及蒽环类药物,采用吉西他滨1000mg/m2静脉注射,第1、8天;顺铂30mg/m2静脉注射第1～3天,21d为1个周期,2个周期后评价疗效,至少应用2个周期。结果 36例中,完全缓解1例(2.8%),部分缓解14例(38.9%),稳定11例(30.6%),进展10例(27.8%),中位疾病进展时间6个月,中位生存时间14个月,1a生存率58%。主要不良反应为骨髓抑制和胃肠道反应。结论吉西他滨联合顺铂对蒽环类及紫杉醇类均耐药的转移性乳腺癌有较好的近期疗效,不良反应能够耐受,是一种效的解救方案。
Objective To observe the efficacy and side effects of gemcitabine combined with cisplatin in the treatment of anthracycline and paclitaxel-resistant metastatic breast cancer. Methods Thirty-six patients with advanced breast cancer were treated with paclitaxel and anthracyclines. Gemcitabine was administered intravenously at 1000 mg / m2 on days 1 and 8; on days 1 to 3 after cisplatin 30 mg / m2 iv administration for one cycle After 2 cycles evaluation of efficacy, at least 2 cycles. Results In 36 cases, complete remission was achieved in 1 case (2.8%), partial remission in 14 cases (38.9%), stabilization in 11 cases (30.6%), progression in 10 cases (27.8%), progression of median disease in 6 months Survival time 14 months, 1a survival rate of 58%. The main adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Gemcitabine combined with cisplatin has good short-term curative effect on anthracycline and paclitaxel-resistant metastatic breast cancer, and its adverse reaction is tolerable. It is a effective rescue plan.